Muutke küpsiste eelistusi

Midlife Health - Current Concepts and Challenges for the Future: Proceedings of the 5th European Congress on Menopause, Copenhagen, 1-5 July 2000 [Kõva köide]

Edited by , Edited by
  • Formaat: Hardback, 240 pages, kaal: 585 g, indexes
  • Sari: International Congress S. v. 1229
  • Ilmumisaeg: 17-Apr-2002
  • Kirjastus: Elsevier Health Sciences
  • ISBN-10: 0444507078
  • ISBN-13: 9780444507075
Teised raamatud teemal:
  • Kõva köide
  • Hind: 168,05 €*
  • * saadame teile pakkumise kasutatud raamatule, mille hind võib erineda kodulehel olevast hinnast
  • See raamat on trükist otsas, kuid me saadame teile pakkumise kasutatud raamatule.
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Lisa soovinimekirja
Midlife Health - Current Concepts and Challenges for the Future: Proceedings of the 5th European Congress on Menopause, Copenhagen, 1-5 July 2000Suurem pilt
  • Formaat: Hardback, 240 pages, kaal: 585 g, indexes
  • Sari: International Congress S. v. 1229
  • Ilmumisaeg: 17-Apr-2002
  • Kirjastus: Elsevier Health Sciences
  • ISBN-10: 0444507078
  • ISBN-13: 9780444507075
Teised raamatud teemal:
Püsilink: https://www.kriso.ee/db/9780444507075.html
Märksõnad:
The world population is growing and ageing. This is particularly true for the female part and the World Health Organisation has predicted a 4-fold increase of women over 50 by the year 2030. Already by the age of 50 women start to outnumber men, and after age 75 there are twice as many women as men. Current knowledge of women's health issues after the age of 50 is vital, as women will be the most common patients almost irrespective of medical specialty! Some of the burning questions and hot issues discussed during the 5th European Congress on the Menopause & Andropause are: Prevention is better than cure; how could this be done cost-effectively ; Is this applicable to all major diseases ; How should prevention be organised ; Can results from one population be transferred directly to another ; What is the preventive role of hormone replacement therapy (HRT) in women ; Could HRT also be used to treat common diseases and disorders and if so, which form is best used and for how long ; and Could HRT also be advocated for men?
Preface v
Contents vii
I. Endocrinology, physiology and psychology in mid ages
Metabolic and endocrine changes in climacteric women
3(6)
A. Milewicz
M. Demissie
Psychosocial stress and male gonadal function
9(8)
P.M. Nilsson
P. Bauenholm
5-Androgens and postmenopause: effects of 6 months DHEA supplementation in postmenopausal women
17(8)
A.R. Genazzani
B. Quirici
F. Bernardi
I. Lombardi
A. Tonetti
E. Casarosa
M. Liut
S. Puccetti
M. Pieri
M. Stomati
Menopause: loss of self-esteem?
25(6)
M. Lachowsky
How to assess quality of life? Aspects of methodology
31(8)
E.M. Alder
Depression in midlife women: what have we learned from longitudinal studies?
39(6)
A. Mariella
E.S. Mitchell
N.F. Woods
HRT and cognitive function
45(8)
R. Erkkola
P. Polo-Kantola
Middle-aged men: sexuality and well-being Lecture given on the 5th European Congress on Menopause Copenhagen, Denmark, 1-4 July, 2000
53(10)
A. Thiele
II. Osteoporosis
Techniques for measuring bone mineral density
63(6)
J.J. Stepan
Postmenopausal osteoporosis: biochemical markers for monitoring of bone metabolism
69(12)
N.H. Bjarnason
III. Hormones and cardiovascular disease
Estrogen and apoptosis in atherosclerosis
81(14)
M. Barton
M.M. Kockx
Inflammation in atherosclerosis and acute coronary syndromes
95(8)
J. Gram
HRT effects on inflammatory markers: is chronic inflammation a contra-indication for HRT?
103(6)
C. Kluft
Nutritional modification of cardiovascular disease risk
109(6)
M. Osler
Hypertension and HRT
115(8)
A.O. Mueck
Motion: there is no relation between estrogen deficiency and cardiovascular morbidity. Some introductory remarks by the moderator Dr. Amos Pines to a debate between Dr. John Stevenson (for) and Dr. Trudy Bush (against)
123(4)
A. Pines
Long-term hormone replacement therapy use is no longer controversial
127(8)
S. Palacios
IV. Breast and endometrium
Risk of breast cancer with hormone replacement therapy
135(8)
K.B. Michels
Is there a place for progestin agents in breast cancer prevention?
143(8)
A. Compel
D. Leuy
M. Chaouat
A. Kazem
D. Hugol
E. Darai
Y. Decroix
W. Rostene
Managing menopausal symptoms after breast cancer
151(6)
E. Kubista
M. Seifert
Cancer in the family and implications for hormone replacement therapy
157(6)
P.A. Fasching
C. Nestle-Kramling
C. Brumm
S. Djahansouzi
M.W. Beckmann
Ultrasound: a useful tool?
163(8)
W. Haenggi
L. Raio
Biopsy techniques
171(8)
S. Rozenberg
C. Fellemans
M. Kroll
R. Gevers
J. Vandromme
V. Wound healing
Ovarian hormone deficiency and wound healing
179(10)
M. Calvin
VI. Information and education
Clinical use of soy products
189(6)
P. Albertazzi
Cimicifuga racemosa: a selective estrogen receptor modulator?
195(12)
D. Seidlova-Wuttke
H. Jarry
V. Viereck
I. Heiden
V. Christoffel
B. Spengler
W. Wuttke
Attitudes towards menopause and hormone replacement therapy in different cultures
207(8)
S. Krishna
The Consensus Conference and technical report series
215(6)
B.-I. Nesheim
Whom and how should we inform?
221(6)
T. Moskovic
Author index 227(2)
Keyword index 229